HYPERTENSION, DIABETES AND HEART FAILURE
More AF in new diabetes patients in VALUE trial
June 18, 2007 – Milan, Italy – A retrospective analysis of the VALUE trial found a higher risk of developing atrial fibrillation (AF) in the high-risk patients with hypertension, and the investigators propose that this development of AF may be the reason for the high risk of developing heart failure in this patient population. The data were presented by Prof. T. Aksnes, Ullevaal University Hospital, Oslo, Norway.
MORE>> |
The lecture
Fetal Programming
Fetal programming and low birth weight has been clearly shown to be associated with a number of factors that lead to a higher risk for cardiovascular (CV) and metabolic disorders and diseases, including hypertension, type 2 diabetes mellitus (T2DM), hyperlipidemia, insulin resistance, metabolic syndrome, vascular dysfunction, and coronary heart disease (CHD).
MORE>> |
Topical Workshop
New Insights into Hypertension in Adolescents
Lectures in this topical workshop provided insights into the relationships between high blood pressure and metabolic abnormalities and weight abnormalities in adolescents.
MORE>> |
Clinical Trials
BP-independent effect of olmesartan to reduce plaque volume seen in MORE study
June 18, 2007 – Milan, Italy – Olmesartan was associated with a greater reduction in the secondary endpoint of plaque volume in patients with a baseline volume above the median level, compared to treatment with atenolol, while the reductions in the primary endpoint of changes in carotid intima media thickness were similar with both drugs.
MORE>> |
|
 |
HYPERTENSION AND RENAL DISEASE
Dual-channel CCB more effective
for renoprotection
in hypertension
June 18, 2007 – Milan, Italy – Cilnidipine, a blocker of the L and N calcium channels, was more effective than amlodipine in preventing renal disease in patients with hypertension already treated with inhibitors of the renin angiotensin system (RAS).
MORE>> |
lifestyle
New model of preventive cardiology yields important improvements in patients and families
The nurse-led multidisciplinary EUROACTION family-based program achieved significantly better lifestyle changes for coronary and high-risk patients, including improved blood pressure control, healthier diet, reduction in central obesity, and increased physical activity, compared to usual care.
MORE>> |
Obesity
Insulin resistance in obese children
and adolescents
Presentations in this session provided insights regarding the effects of insulin resistance in obese children and adolescents, the role of adrenergic activity in the development of obesity, the effects of sibutramine on blood pressure, and the role of insulin resistance and adrenergic activity in the development of organ damage.
MORE>> |
Clinical Trials
Single pill treatment with amlodipine/atorvastatin safe and effective across different races
June 18, 2007 – Milan, Italy – The 14-week multicenter, open label, titration-to-goal GEMINI-AALA study in patients with hypertension and dyslipidemia showed that a single pill with amlodipine/atorvastatin with eight different doses showed that 52% of patients reached both blood pressure and LDL-C goals, 61.3% reached blood pressure goals, and 87.1% reached LDL-C goals. These reductions were similar across different racial groups.
MORE>> |
|
